While GLP-1 agonists like Wegovy and Ozempic are now widely embraced and extensively utilized, a growing body of research is bringing to light certain potentially concerning adverse effects. This includes novel investigations specifically examining a correlation with vision impairment.
These pharmacologic agents derive their nomenclature from their mechanism of action, which involves emulating the effects of the endogenous glucagon-like peptide-1 (GLP-1) hormone. This mimicry serves to modulate appetite suppression, facilitate digestive processes, and regulate glycemic control. Consequently, they have been broadly recommended for therapeutic interventions aimed at weight reduction and the management of diabetes mellitus.
Nevertheless, reports linking GLP-1 medications and their principal constituent, semaglutide, to visual disturbances are experiencing an upward trend. This surge in reported incidents has prompted regulatory bodies in the United Kingdom and Europe to initiate reviews of the associated risks, based on the available scientific data.
Within the scope of this recent study, a collaborative team of academics from various Canadian universities undertook an analysis of adverse event records meticulously compiled by the U.S. Food and Drug Administration (FDA) over a seven-year period, spanning from 2017 to 2024. Their focus was on identifying instances of ischemic optic neuropathy (ION).
This uncommon condition possesses the potential to induce abrupt and total loss of vision, stemming from an insufficient blood supply to the optic nerve. In certain circumstances, this deficit can result in irreversible damage.
The research objective was to ascertain the frequency of ION occurrences among individuals receiving different semaglutide formulations: Wegovy, prescribed for weight management; Ozempic, designated for type 2 diabetes treatment; and Rybelsus, also indicated for type 2 diabetes management.
“These discoveries build upon our preceding global assessment and, whereas prior investigations identified solely an agent-specific correlational link, this present study furnishes the inaugural evidence of a formulation- and dose-dependent risk of ION. The most pronounced association was discerned with Wegovy,” the investigators articulate in their published findings.
The statistical methodologies employed by the research cadre revealed that the likelihood of an ION complaint attributable to Wegovy was nearly fivefold greater compared to Ozempic. Conversely, no discernible correlation was established between Rybelsus and the occurrence of ION.
This disparity is considerable; however, it is imperative to situate these figures within their appropriate context. The FDA repository subjected to the researchers’ scrutiny encompassed over 30 million documented adverse events. Within this vast dataset, a total of 28 cases were identified that implicated Wegovy in ION, while 47 cases linked Ozempic to this condition.
Although the absolute number of Ozempic-related cases is higher, it is noteworthy that Ozempic has been available and prescribed for a substantially longer duration than Wegovy. Notwithstanding this temporal difference, the researchers identified the most robust ION signal associated with Wegovy, a finding that persisted even after accounting for demographic variables such as age and sex. Based on the reported incidents, the statistical odds of developing ION among Wegovy users were found to be 4.74 times greater than among Ozempic users.
A distinct pattern emerged concerning gender distinctions: Male individuals receiving any form of semaglutide exhibited approximately a threefold higher propensity for reporting ION cases compared to their female counterparts utilizing GLP-1 agonists.
While these findings represent correlational associations derived from a specific FDA database—and not definitive risk estimations applicable to the global populace prescribed semaglutide—they nonetheless engender apprehension among experts. These professionals advocate for the necessity of further in-depth investigations.
“These revelations accentuate a potential safety concern that appears to be contingent upon dosage, necessitating urgent prospective evaluation to inform both prescribing practices and regulatory frameworks,” the researchers assert.
The investigative team did not delve into the precise causative mechanisms that might link GLP-1 medications to visual impairment in this particular study. However, they have posited several potential hypotheses. One such theory suggests that Wegovy, which has received approval for administration at higher dosages than other GLP-1 agents, might induce reductions in blood pressure. This hypotensive effect could, in turn, potentially compromise blood flow to the ocular structures.
This particular hypothesis represents a fertile area for subsequent research efforts. In the interim, scientific inquiry is progressively constructing a multifaceted understanding of GLP-1 medications. Beyond their primary therapeutic objectives, these agents have been associated with a spectrum of ancillary biological sequelae, ranging from a diminished risk of certain cancers to an increased susceptibility to depressive symptoms.
In a concurrently published annotated commentary, researchers affiliated with the University of Southampton in the United Kingdom, who were not directly involved in the primary study, discuss the critical imperative of balancing the immediate demand for effective anti-obesity interventions with an equally pressing obligation to ensure the safety profile of these treatments.
“Consequently, further studies that provide such granular and nuanced data are highly warranted,” the commentators conclude. “This is essential for a more comprehensive understanding of the ocular effects of anti-obesity pharmacotherapies, particularly given their escalating utilization.”
